scholarly journals Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen

Diabetologia ◽  
1995 ◽  
Vol 38 (5) ◽  
pp. 592-598 ◽  
Author(s):  
F. S. Nielsen ◽  
L. N. J�rgensen ◽  
M. Ipsen ◽  
A. I. Voldsgaard ◽  
H. -H. Parving
Keyword(s):  
Human Insulin ◽  
Insulin Analogue ◽  
Insulin Regimen ◽  
Bolus Insulin ◽  
Basal Bolus

scholarly journals Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen

Diabetologia ◽  
1995 ◽  
Vol 38 (5) ◽  
pp. 592-598
Author(s):  
F. S. Nielsen ◽  
L. N. J�rgensen ◽  
M. Ipsen ◽  
A. I. Voldsgaard ◽  
H.-H. Parving
Keyword(s):  
Human Insulin ◽  
Insulin Analogue ◽  
Insulin Regimen ◽  
Bolus Insulin ◽  
Basal Bolus

Switching to basal-bolus insulin therapy is effective and safe in long-term type 2 diabetes patients inadequately controlled with other insulin regimens

2013 ◽  
Vol 60 (5) ◽  
pp. 249-253
Author(s):  
Irene Vinagre ◽  
Juan Sánchez-Hernández ◽  
José Luis Sánchez-Quesada ◽  
Miguel Ángel María ◽  
Alberto de Leiva ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Bolus Insulin ◽  
Basal Bolus ◽  
Term Type ◽  
Diabetes Patients

scholarly journals Comparison of an Electronic Glycemic Management System Versus Provider-Managed Subcutaneous Basal Bolus Insulin Therapy in the Hospital Setting

2016 ◽  
Vol 11 (1) ◽  
pp. 12-16 ◽  
Author(s):  
Joseph Aloi ◽  
Bruce W. Bode ◽  
Jagdeesh Ullal ◽  
Paul Chidester ◽  
Raymie S. McFarland ◽  
...  
Keyword(s):  
Insulin Therapy ◽  
Management System ◽  
Standard Treatment ◽  
Hospital Setting ◽  
Insulin Regimen ◽  
Therapy Outcomes ◽  
System Versus ◽  
Bolus Insulin ◽  
Basal Bolus ◽  
Glycemic Management

Background: American Diabetes Association (ADA) guidelines recommend a basal bolus correction insulin regimen as the preferred method of treatment for non–critically ill hospitalized patients. However, achieving ADA glucose targets safely, without hypoglycemia, is challenging. In this study we evaluated the safety and efficacy of basal bolus subcutaneous (SubQ) insulin therapy managed by providers compared to a nurse-directed Electronic Glycemic Management System (eGMS). Method: This retrospective crossover study evaluated 993 non-ICU patients treated with subcutaneous basal bolus insulin therapy managed by a provider compared to an eGMS. Analysis compared therapy outcomes before Glucommander (BGM), during Glucommander (DGM), and after Glucommander (AGM) for all patients. The blood glucose (BG) target was set at 140-180 mg/dL for all groups. The safety of each was evaluated by the following: (1) BG averages, (2) hypoglycemic events <40 and <70 mg/dL, and (3) percentage of BG in target. Result: Percentage of BG in target was BGM 47%, DGM 62%, and AGM 36%. Patients’ BGM BG average was 195 mg/dL, DGM BG average was 169 mg/dL, and AGM BG average was 174 mg/dL. Percentage of hypoglycemic events <70 mg/dL was 2.6% BGM, 1.9% DGM, and 2.8% AGM treatment. Conclusion: Patients using eGMS in the DGM group achieved improved glycemic control with lower incidence of hypoglycemia (<40 mg/dL and <70 mg/dl) compared to both BGM and AGM management with standard treatment. These results suggest that an eGMS can safely maintain glucose control with less hypoglycemia than basal bolus treatment managed by a provider.

scholarly journals Hypoglycemia Incidence and Factors Associated in a Cohort of Patients With Type 2 Diabetes Hospitalized in General Ward Treated With Basal Bolus Insulin Regimen Assessed by Continuous Glucose Monitoring

2019 ◽  
Vol 14 (2) ◽  
pp. 233-239 ◽  
Author(s):  
Ana María Gómez ◽  
Angélica Imitola Madero ◽  
Diana Cristina Henao Carrillo ◽  
Martín Rondón ◽  
Oscar Mauricio Muñoz ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Monitoring ◽  
Glycemic Variability ◽  
General Ward ◽  
Insulin Regimen ◽  
Factors Associated ◽  
Bolus Insulin ◽  
Mean Glucose ◽  
Basal Bolus

Introduction: Continuous glucose monitoring (CGM) is a better tool to detect hyper and hypoglycemia than capillary point of care in insulin-treated patients during hospitalization. We evaluated the incidence of hypoglycemia in patients with type 2 diabetes (T2D) treated with basal bolus insulin regimen using CGM and factors associated with hypoglycemia. Methods: Post hoc analysis of a prospective cohort study. Hypoglycemia was documented in terms of incidence rate and percentage of time <54 mg/dL (3.0 mmol/L) and <70 mg/dL (3.9 mmol/L). Factors evaluated included glycemic variability analyzed during the first 6 days of basal bolus therapy. Results: A total of 34 hospitalized patients with T2D in general ward were included, with admission A1c of 9.26 ± 2.62% (76.8 ± 13 mmol/mol) and mean blood glucose of 254 ± 153 mg/dL. There were two events of hypoglycemia below 54 mg/dL (3.0 mmol/L) and 11 events below 70 mg/dL (3.9 mmol/L) with an incidence of hypoglycemic events of 0.059 and 0.323 per patient, respectively. From second to fifth day of treatment the percentage of time in range (140-180 mg/dL, 7.8-10.0 mmol/L) increased from 72.1% to 89.4%. Factors related to hypoglycemic events <70 mg/dL (3.9 mmol/L) were admission mean glucose (IRR 0.86, 95% CI 0.79, 0.95, P < .01), glycemic variability measured as CV (IRR 3.12, 95% CI 1.33, 7.61, P < .01) and SD, and duration of stay. Conclusions: Basal bolus insulin regimen is effective and the overall incidence of hypoglycemia detected by CGM is low in hospitalized patients with T2D. Increased glycemic variability as well as the decrease in mean glucose were associated with events <70 mg/dL (3.9 mmol/L).

Sliding-Scale Insulin (SSI) vs. Basal/Basal-Bolus Insulin (B-BI) Therapy in Long-Term Care (LTC): Results from a 21-Day Intervention Trial

2015 ◽  
Vol 16 (3) ◽  
pp. B28
Author(s):  
T.S. Dharmarajan ◽  
T.S. Dharmarajan ◽  
D. Mahajan ◽  
A. Zambrano ◽  
R. Fischer ◽  
...  
Keyword(s):  
Long Term Care ◽  
Intervention Trial ◽  
Term Care ◽  
Sliding Scale ◽  
Bolus Insulin ◽  
Basal Bolus

scholarly journals Sliding Scale Insulin vs Basal-Bolus Insulin Therapy in Long-Term Care: A 21-Day Randomized Controlled Trial Comparing Efficacy, Safety and Feasibility

2016 ◽  
Vol 17 (3) ◽  
pp. 206-213 ◽  
Author(s):  
Thiruvinvamalai S. Dharmarajan ◽  
Dheeraj Mahajan ◽  
Annie Zambrano ◽  
Bikash Agarwal ◽  
Rachel Fischer ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Insulin Therapy ◽  
Long Term Care ◽  
Controlled Trial ◽  
Term Care ◽  
Randomized Controlled ◽  
Sliding Scale ◽  
Bolus Insulin ◽  
Basal Bolus
Sign in / Sign up

Export Citation Format

Share Document